SUBSCRIBE
SUBSCRIBE

Indications

PRESS RELEASES
Press Releases
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
February 24, 2026
 · 
19 min read
Press Releases
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
February 24, 2026
 · 
28 min read
Press Releases
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052
February 24, 2026
 · 
5 min read
Press Releases
Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer
February 23, 2026
 · 
15 min read
Press Releases
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
February 23, 2026
 · 
6 min read
Press Releases
New indication in pediatric patients, including term neonates for Guerbet’s half-dose GBCA, Elucirem™ (Gadopiclenol) Injection
February 22, 2026
 · 
8 min read
Press Releases
AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform
February 19, 2026
 · 
8 min read
Press Releases
Pilatus Biosciences Receives FDA Fast Track Designation for Metabolic Checkpoint Inhibitor PLT012 in Hepatocellular Carcinoma
February 19, 2026
 · 
4 min read
Press Releases
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
February 19, 2026
 · 
10 min read
Press Releases
Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications
February 18, 2026
 · 
7 min read
Press Releases
FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction
February 18, 2026
 · 
8 min read
Press Releases
Health Canada Approves KEYTRUDA SC™, a subcutaneous formulation of pembrolizumab across multiple cancer indications
February 17, 2026
 · 
7 min read
Press Releases
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
February 17, 2026
 · 
6 min read
Press Releases
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting
February 17, 2026
 · 
5 min read
Press Releases
Trethera to Highlight Clinical Momentum and Indication Expansion at Biocom Global Partnering & Investor Conference
February 12, 2026
 · 
4 min read
Press Releases
Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
February 11, 2026
 · 
8 min read
Press Releases
KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
February 11, 2026
 · 
19 min read
Press Releases
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
February 11, 2026
 · 
4 min read
Press Releases
Akeso’s IL-4Rα/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications
February 11, 2026
 · 
5 min read
Press Releases
BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart
February 10, 2026
 · 
4 min read
Load More